Method Development of NDMA and NDEA Quantification in Sartan Drug by LC-MS/MS
Postery | 2019 | Agilent TechnologiesInstrumentace
LC/MS, LC/MS/MS, LC/QQQ
ZaměřeníFarmaceutická analýza
VýrobceAgilent Technologies
Klíčová slovandma, ndea, ultivo, api, sartan, gis, method, irbesartan, valsartan, drug, recovery, analytes, sensitivity, volumn, quantitative, edqm, standard, loq, conditions, agilent, both, separation, high, linearity, genotoxic, quantification, inaccurate, precision, internal, lots, corona, target, drawn, accurate, nitrosodimethylamine, centrifugation, exhibited, reprint, chromatographic, official, switched, apci, demonstrating, issue, poster, action, between, membrane, discussion, assessed
Podobná PDF
Nitrosamine Impurities Application Guide - Confidently Detect and Quantify Mutagenic Impurities in APIs and Drug Products
2020|Agilent Technologies|PříručkyPrezentace
Nitrosamine Impurities Application Guide Confidently Detect and Quantify Mutagenic Impurities in APIs and Drug Products Sartan-Based Losartan Valsartan Candesartan Telmisartan Metformin Ranitidine Nitrosamines are formed by chemical reactions that occur during API manufacturing whether from starting materials, intermediates, reactants, reuse…
Klíčová slova
back, backndma, ndmaneipa, neipafda, fdandea, ndeandipa, ndipandba, ndbametformin, metforminnitrosamine, nitrosamineintroduction, introductionapi, apivalsartan, valsartanquant, quantbest, bestdichloromethan
Highly Sensitive LC/MS/MS Method for the Simultaneous Quantification of Mutagenic Azido Impurity Analogues in Five Different Sartan APIs and Formulations
2022|Agilent Technologies|Aplikace
Application Note Pharmaceuticals Highly Sensitive LC/MS/MS Method for the Simultaneous Quantification of Mutagenic Azido Impurity Analogues in Five Different Sartan APIs and Formulations Detection of regulated genotoxic impurities from the drug manufacturing process Authors Kartheek Srinivas Chidella, Saikat Banerjee, and…
Klíčová slova
azbt, azbtazbc, azbcsartan, sartanimpurity, impurityazido, azidoapis, apiscandesartan, candesartandad, dadolmesartan, olmesartanapi, apichromatogram, chromatogramlosartan, losartanvalsartan, valsartanimpurities, impuritiesppm
Determination of Nitrosamines in Active Pharmaceutical Ingredients
2020|Agilent Technologies|Aplikace
Application Note Pharmaceutical Determination of Nitrosamines in Active Pharmaceutical Ingredients High flexibility and performance at lowest cost using the Agilent 1260 Infinity II Prime LC with the Agilent Ultivo LC/TQ for LC/MS analysis Author Edgar Naegele Agilent Technologies, Inc. Abstract…
Klíčová slova
nitrosamine, nitrosamineaccuracy, accuracyndba, ndbanitrosamines, nitrosaminesnmor, nmornmea, nmeandpa, ndpandea, ndeaultivo, ultivondma, ndmanpip, npipvalsartan, valsartanpharmaceutical, pharmaceuticalgti, gtinitroso
Analysis of Pharmaceuticals’ Impurity - Regulations and Analysis for Carcinogenic Substances -
2020|Shimadzu|Příručky
Application Note No. 62 Analysis of Pharmaceuticals’ Impurity - Regulations and Analysis for Carcinogenic Substances Dheeraj Handique *a), Nitish Suryawanshi *a), Crystal Yeong *b), Cynthia Lahey *b), Shailendra Rane *a), Deepti Bhandarkar *a), Anant Lohar *a), Gao Jie san *c),…
Klíčová slova
ndma, ndmandea, ndeacarcinogenic, carcinogenicsubstances, substancesmutagenic, mutagenicmms, mmsems, emsimpurity, impuritymode, modeims, imsdrug, drugmutagenicity, mutagenicityolmesartan, olmesartanndba, ndbapharmaceuticals
